Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Resources
-
Expand to See More
V+R AIDS 2026 OPERA Infographic
Comprative Real-world effectiveness of Vocabria + Rekambys versus BIC/FTC/TAF
V+R CROI VOLITION Poster
Early Switch to CAB+RPV LA in Treatment-Naive Adults With HIV-1: Month 11 outcomes from VOLITION
NP-IE-CBR-PSTR-260002
V+R CROI OPERA Poster
Body Mass Index and Virologic Outcomes in Individuals on CAB+RPV LA in the OPERA Cohort
NP-IE-CBR-PSTR-260001
V+R - VOLITION Infographic
VOLITION Infographic summarising DoC and Outcomes Data at Month 11
PM-IE-CBR-LBND-260002
Nurse Welcome Booklet
A guide to administering cabotegravir▼ + rilpivirine▼ long-acting injectables
PM-IE-CBR-BKLT-250002
CROI 2025 Key Data Summary
Summary deck looking at the OPERA 3 year availability data, OPERA women subgroup data and CARES 96 week data.
PM-IE-CBR-PPT-250001
Patient Resources
-
Expand to See More
Vocabria + Rekambys Patient Information Booklet
A printed booklet to provide practical information for patients post-prescription of Vocabria + Rekambys. This is to support patients to understand the treatment and ensure people living with HIV are aware of their role in treatment success.
NP-IE-CBR-LBND-230001
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via the online form at gsk.public.reportum.com
▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
REKAMBYS (rilpivirine long acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies.
All other trademarks are owned by the ViiV Healthcare group.
©2026 GSK group of companies. All rights reserved.
Date of preparation: September 2026 | PM-IE-CBR-WCNT-240008
